Systemic Administration of GPI 15427, a Novel Poly(ADP-Ribose) Polymerase-1 Inhibitor, Increases the Antitumor Activity of Temozolomide against Intracranial Melanoma, Glioma, Lymphoma

Clinical Cancer Research

Volumn 9, Issue 14, 2003, Pages 5370-5379

  Tentori, Lucio ^a   Leonetti, Carlo ^b   Scarsella, Marco ^b   D'Amati, Giulia ^c   Vergati, Matteo ^a   Portarena, Ilaria ^a   Xu, Weizheng ^d   Kalish, Vincent ^d   Zupi, Gabriella ^b   Zhang, Jie ^d   Graziani, Grazia ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d GUILFORD PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; GPI 15427; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; POLY(ADP RIBOSE) POLYMERASE 1 INHIBITOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; LIFESPAN; LYMPHOMA CELL; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; DACARBAZINE; DRUG SYNERGISM; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; LYMPHOMA; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; POLY(ADP-RIBOSE) POLYMERASES; SURVIVAL RATE; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 10744233684     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Bleehen, N. M., Newlands, E. S., Lee, S. M., Thatcher, N., Selby, P., Calvert, A. H., Rustin, G. J., Brampton, M., and Stevens, M. F. Cancer Res. Campaign Phase II trial of temozolomide in metastatic melanoma. J. Clin. Oncol., 13: 910-913, 1995.
2. Cohen, M. H., Johnson, J. R., and Middleton, M. R. Temozolomide for advanced, metastatic melanoma. J. Clin. Oncol., 18: 2185, 2000.
3. Middleton, M. R., Grob, J. J., Aaronson, N., Fierlbeck, G., Tilgen, W., Seiter, S., Gore, M., Aamdal, S., Cebon, J., Coates, A., Dreno, B., Henz, M., Schadendorf, D., Kapp, A., Weiss, J., Fraass, U., Statkevich, P., Muller, M., and Thatcher, N. Randomized Phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J. Clin. Oncol., 18: 158-166, 2000.
4. Biasco, G., Pantaleo, M. A., and Casadei, S. Treatment of brain metastases of malignant melanoma with temozolomide. N. Engl. J. Med., 345: 621-622, 2001.
5. Douglas, J. G., and Margolin, K. The treatment of brain metastases from malignant melanoma. Semin. Oncol., 29: 518-524, 2002.
6. Yung, W. K., Prados, M. D., Yaya-Tur, R., Rosenfeld, S. S., Brada, M., Friedman, H. S., Albright, R., Olson, J., Chang, S. M. O'Neill, A. M., Friedman, A. H., Bruner, J., Yue, N., Dugan, M., Zaknoen, S., and Levin, V. A. Multicenter Phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J. Clin. Oncol., 17: 2762-2771, 1999.
7. Batchelor, T. Temozolomide for malignant brain tumours. Lancet, 355: 1115-1116, 2000.
8. Friedman, H. S., Kerby, T., and Calvert, H. Temozolomide and treatment of malignant glioma. Clin. Cancer Res., 6: 2585-2597, 2000.
9. Osoba, D., Brada, M., Yung, W. K., and Prados, M. Health-related quality of life in patients treated with temozolomide versus procarbazine for recurrent glioblastoma multiforme. J. Clin. Oncol., 18: 1481-1491, 2000.
10. Prados, M. D. Future directions in the treatment of malignant gliomas with temozolomide. Semin. Oncol., 27 (3 Suppl. 6): 41-46, 2000.
11. Brada, M., Hoang-Xuan, K., Rampling, R., Dietrich, P. Y., Dirix, L. Y., Macdonald, D., Heimans, J. J., Zonnenberg, B. A., Bravo-Marques, J. M., Henriksson, R., Stupp, R., Yue, N., Bruner, J., Dugan, M., Rao, S., and Zaknoen, S. Multicenter Phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Ann. Oncol., 12: 259-266, 2001.
12. Chinot, O. L., Honore, S., Dufour, H., Barrie, M., Figarella-Branger, D., Muracciole, X., Braguer, D., Martin, P. M., and Grisoli, F. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy. J. Clin. Oncol., 19: 2449-2455, 2001.
13. MacDonald, D. R. Temozolomide for recurrent high-grade glioma. Semin. Oncol., 28 (4 Suppl. 13): 3-12, 2001.
14. Dinnes, J., Cave, C., Huang, S., and Milne, R. A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br. J. Cancer, 86: 501-505, 2002.
15. Gaya, A., Rees, J., Greenstein, A., and Stebbing, J. The use of temozolomide in recurrent malignant gliomas. Cancer Treat. Rev., 28: 115-120, 2002.
16. Lashford, L. S., Thiesse, P., Jouvet, A., Jaspan, T., Couanet, D., Griffiths, P. D., Doz, F., Ironside, J., Robson, K., Hobson, R., Dugan, M., Pearson, A. D., Vassal, G., and Frappaz, D. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study. J. Clin. Oncol., 20: 4684-4691, 2002.
17. Trent, S., Kong, A., Short, S. C., Traish, D., Ashley, S., Dowe, A., Hines, F., and Brada, M. Temozolomide as second-line chemotherapy for relapsed gliomas. J. Neurooncol., 57: 247-251, 2002.
18. Reni, M., Ferreri, A. J., Landoni, C., and Villa, E. Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma. J. Natl. Cancer Inst. (Bethesda), 92: 575-576, 2000.
19. Herrlinger, U., Kuker, W., Platten, M., Dichgans, J., and Weller, M. First-line therapy with temozolomide induces regression of primary CNS lymphoma. Neurology, 58: 1573-1574, 2002.
20. Lerro, K. A., and Lacy, J. Case report: a patient with primary CNS lymphoma treated with temozolomide to complete response. J. Neurooncol., 59: 165-168, 2002.
21. Abrey, L. E., and Christodoulou, C. Temozolomide for treating brain metastases. Semin. Oncol., 28 (4 Suppl. 13): 34-42, 2001.
22. Antonadou, D., Paraskevaidis, M., Sarris, G., Coliarakis, N., Economou, I., Karageorgis, P., and Throuvalas, N. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol., 20: 3644-3650, 2002.
23. Prados, M. D. Temozolomide in combination with other cytotoxic agents. Semin. Oncol., 28: 24-33, 2001.
24. Atkins, M. B., Gollob, J. A., Sosman, J. A., McDermott, D. F., Tutin, L., Sorokin, P., Parker, R. A., and Mier, J. W. A Phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin-2, and IFN-α 2B in patients with metastatic melanoma. Clin. Cancer Res., 8: 3075-3081, 2002.
25. Bafaloukos, D., Gogas, H., Georgoulias, V., Briassoulis, E., Fountzilas, G., Samantas, E., Kalofonos, C., Skarlos, D., Karabelis, A., and Kosmidis, P. Temozolomide in combination with docetaxel in patients with advanced melanoma: a Phase II study of the Hellenic Cooperative Oncology Group. J. Clin. Oncol., 20: 420-425, 2002.
26. Hwu, W. J., Krown, S. E., Panageas, K. S., Menell, J. H., Chapman, P. B., Livingston, P. O., Williams, L. J., Quinn, C. J., and Houghton, A. N. Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. J. Clin. Oncol., 20: 2610-2615, 2002.
27. Stupp, R., Dietrich. P. Y., Ostermann Kraljevic, S., Pica, A., Maillard, I., Maeder, P., Meuli, R., Janzer, R., Pizzolato, G., Miralbell, R., Porchet, F., Regli, L., de Tribolet, N., Mirimanoff, R. O., and Leyvraz, S. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J. Clin. Oncol., 20: 1375-1382, 2002.
28. Newlands, E. S., Stevens, M. F., Wedge, S. R., Wheelhouse, R. T., and Brock, C. Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat. Rev., 23: 35-61, 1997.
29. D'Atri, S., Tentori, L., Lacal, P. M., Graziani, G., Pagani, E., Benincasa, E., Zambruno, G., Bonmassar, E., and Jiricny, J. Involvement of the mismatch repair system in temozolomide-induced apoptosis. Mol. Pharmacol., 54: 334-341, 1998.
30. 2-M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res., 61: 1957-1963, 2001.
31. 6-benzylguanine and its role in chemotherapy. Clin. Cancer Res., 3: 837-847, 1997.
32. 6-benzylguanine for patients with recurrent or progressive malignant glioma. J. Clin. Oncol., 18: 3522-3528, 2000.
33. 6-alkylguanine-DNA alkyltransferase activity. Br. J. Cancer, 74: 1030-1036, 1996.
34. 6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol. Pharmacol., 52: 249-258. 1997.
35. Liu, L., Taverna, P., Whitacre, C., M., Chatterjee, S., and Gerson, S. L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and -proficient colon cancer cells to methylating agents. Clin. Cancer Res., 5: 2908-2917, 1999.
36. Tentori, L., Turriziani, M., Franco, D., Serafino, A., Levati, L., Roy, R., Bonmassar, E., and Graziani, G. Treatment with temozolomide and poly(ADP-ribose) polymerase inhibitors induces early apoptosis and increases base excision repair gene transcripts in leukemic cells resistant to triazene compounds. Leukemia (Baltimore), 13: 901-909, 1999.
37. Tentori, L., and Graziani, G. Pharmacological strategies to increase the antitumor activity of methylating agents. Curr. Med. Chem., 9: 1285-1301, 2002.
38. Tentori, L., Leonetti, C., Scarsella, M., d'Amati, G., Portarena, I., Zupi, G., Bonmassar, E., and Graziani, G. Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site. Blood, 99: 2241-2244, 2002.
39. 2-M cell accumulation induced by temozolomide in malignant glioma cells. Glia, 40: 44-54, 2002.
40. Dantzer, F., Shereiber, V., Niedergang, C., Trucco, C., Flatter, E., De La Rubia, G., Oliver, J., Rolli, V., Ménissier-de Murcia, J., and de Murcia, G. Involvement of poly(ADP-ribose) polymerase in base excision repair. Biochimie, 81: 69-75, 1999.
41. Tentori, L., Portarena, I., Bonmassar, E., Graziani, G. Combined effects of adenovirus-mediated wild-type p53 transduction, temozolomide and poly (ADP-ribose) polymerase inhibitor in mismatch repair deficient and non-proliferating tumor cells. Cell Death Differ., 8: 457-469, 2001.
42. Tentori, L., Portarena, I., Vernole, P., De Fabritiis, P., Madaio, R., Balduzzi, A., Roy, R., Bonmassar, E., and Graziani, G. Effects of single or split exposure of leukemic cells to temozolomide, combined with poly(ADP-ribose) polymerase inhibitors on cell growth, chromosomal aberrations and base excision repair components. Cancer Chemother. Pharmacol., 47: 361-369, 2001.
43. Li, J-H., and Zhang, J. Compounds, Methods and Pharmaceutical Compositions for Treating Cellular Damage such as Neural or Cardiovascular Tissue Damage. Patent Cooperation Treaty (PCT) Publication, Geneva, 2001;WO 01/16137, 2001.
44. Friedman, H. S., Dolan, M. E., Pegg, A. E., Marcelli, S., Keir, S., Catino, J. J., Bigner, D. D., and Schold, S. C., Jr. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res., 55: 2853-2857, 1995.
45. 6-(4-bromothenyl)guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int. J. Cancer, 85: 248-252, 2000.
46. 6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea of temozolomide. Clin. Cancer Res., 7: 421-428, 2001.
47. Boulton, S., Pemberton, L. C., Porteous, J. K., Curtin, N. J., Griffin, R. J., Golding, B. T., and Durkacz, B. W. Potentiation of temozolomide-induced cytotoxicity: a comparative study of the biological effects of poly(ADP-ribose) polymerase inhibitors. Br. J. Cancer, 72: 849-856, 1995.
48. Bowman, K. J., White, A., Golding, B. T., Griffin, R. J., and Curtin, N. J. Potentiation of anti-cancer agent cytotoxicity by the potent poly(ADP-ribose) polymerase inhibitors NU1025 and NU1064. Br. J. Cancer (Phila.), 78: 1269-1277, 1998.
49. Li, J-H., and Zhang, J. PARP inhibitors. I. Drugs, 4: 804-812, 2001.
50. Canan Koch, S. S., Thoresen, L. H., Tikhe, J. G., Maegley, K. A., Almassy, R. J., Li, J., Yu, X. H., Zook, S. E., Kumpf, R. A., Zhang, C., Boritzki, T. J., Mansour, R. N., Zhang, K. E., Ekker, A., Calabrese, C. R., Curtin, N. J., Kyle, S., Thomas, H. D., Wang, L. Z., Calvert, A. H., Golding, B. T., Griffin, R. J., Newell, D. R., Webber, S. E., and Hostomsky, Z. Novel tricyclic poly(ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure. J. Med. Chem., 45: 4961-4974, 2002.
51. Virag, L., and Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev., 54: 375-429, 2002.
52. Miknyoczki, S. J., Jones-Bolin, S., Pritchard, S., Hunter, K., Zhao, H., Wan, W., Ator, M., Bihovsky, R., Hudkins, R., Chatterjee, S., Klein-Szanto, A., Dionne. C., and Ruggeri, B. Chemopotentiation of Temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-Ribose) polymerase inhibitor. Mol. Cancer Ther., 2: 371-382. 2003.
53. Szabo, C., and Dawson. V. L. Role of poly(ADP-ribose) synthetase in inflammation and ischaemia-reperfusion. Trends Pharmacol. Sci., 19: 287-298, 1998.
54. Delaney, C. A., Wang, L. Z., Kyle, S., White, A. W., Calvert, A. H., Curtin, N. J., Durkacz, B. W., Hostomsky, Z., and Newell, D. R. Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. Clin. Cancer Res., 6: 2860-2867, 2000.
55. Tentori, L., Balduzzi, A., Portarena, I., Levati, L., Vemole, P., Gold, B., Bonmassar, E., and Graziani, G. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ., 8: 817-828, 2001.
56. Godeneche, D., Rapp, M., Thierry, A., Laval. F., Madelmont, J. C., Chollet, P., and Veyre, A. DNA damage induced by a new 2-chloroethyl nitrosourea on malignant melanoma cells. Cancer Res., 50: 5898-5903, 1990.
57. Middlemas, D. S., Stewart, C. F., Kirstein, M. N., Poquette, C., Friedman. H. S., Houghton, P. J., and Brent, T. P. Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models. Clin. Cancer Res., 6: 998-1007, 2000.
58. 6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. Clin. Cancer Res., 6: 4110-4118, 2000.